UNSPSC 51263603: Alfuzosin hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H27N5O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75046A1XTN, chemically known as 2-furancarboxamide, n-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-, monohydrochloride (+-)- but more generally known as alfuzosin hydrochloride, which bears US NIH Compound Identifier 71764. The base coompound, Alfuzosin, also comes in simple form.

UNSPSC 51263603 Alfuzosin hydrochloride is a Commodity code that in practice captures pharmaceutical procurement by state and local health agencies, though recent activity under this specific code designation is minimal. The code nominally covers a branded alpha-blocker used to treat benign prostatic hyperplasia; however, state and local governments do not routinely solicit this particular drug through open competitive bidding. When pharmaceutical procurement does occur at the state and local level, it typically flows through existing contracts with major distributors, group purchasing organizations, or cooperative purchasing agreements rather than through individual RFP or IFB processes tied to a single active pharmaceutical ingredient.

The most recent opportunity tagged to this code—Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023—is for naloxone and drug deactivation systems, which falls outside the code's nominal scope and reflects a mismatch between the code designation and the actual procurement. This disconnect suggests either a data-entry error in the county's procurement system or a broad categorical tagging practice that does not align with UNSPSC taxonomy precision. Given the absence of additional opportunities under this code in the recent record and the irrelevance of the single tagged solicitation, this code shows little actionable recent activity for vendors pursuing state and local pharmaceutical supply contracts.